Therapeutic Discovery Articles & Analysis: Older
9 articles found
Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody development. ...
Thus, creating sophisticated models of genetic disorders, studying disease pathogenesis, and testing the efficacy of therapeutic strategies has become increasingly attainable. Additionally, the employment of cutting-edge technologies, like next-generation sequencing (NGS), furthers the scope of zebrafish genome editing services. ...
Thus, creating sophisticated models of genetic disorders, studying disease pathogenesis, and testing the efficacy of therapeutic strategies has become increasingly attainable. Additionally, the employment of cutting-edge technologies, like next-generation sequencing (NGS), furthers the scope of zebrafish genome editing services. ...
Targeted protein degradation (TPD) is a promising strategy in the field of drug discovery. In recent years, targeted protein degradation (TPD) technology has developed rapidly, especially proteolysis targeting chimera (PROTAC), which is the most representative technology of TPD strategy. ...
Why target GPCRs with antibodies? The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of human drug targets. GPCRs play a central role in a plethora of biological processes and are linked to a wide range of therapeutic areas including cancer, diabetes, inflammation, cardiovascular diseases, and chronic pain. Expressed in every type of cell in ...
Further, we are committed to contributing to the greater research community by promoting the use of analysis-ready data that can be utilised in the long-term to power therapeutic discovery. Lifebit’s Platform enables secure data access and usability, and we are proud to promote community best-practices in our work with valued clients including Genomics ...
ByLifebit
Scientists continuously face pressure to purify biologics like protein therapeutics with maximum yield while minimizing cost and developing processes as quickly as possible. ...
In collaboration with Myrio Therapeutics, an antibody discovery company, the researchers developed a PC-CAR against this peptide and showed that these PC-CARs can recognize tumor-specific peptides of different HLA types, which means that this treatment can be applied to patients with different genetic lineages. ...
The regulation of a key signaling pathway provides new mechanisms and therapeutic insights. In addition, UBE2N is a functionally related interacting protein of BRCA1. ...